tbuckley/cabot-search huggingface dataset:
SAT0408 Positive correlation between inflammation on sacroiliac joint mri and serum c-terminal telopeptide of type-i collagen in ankylosing spondylitis but not in non-radiographic axial spondyloarthritis
Authors: KY Kang, YS Hong, JH Ju, S-H Park
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The MRI-determined inflammatory score was suggested as a more objective measure of disease activity than clinical activity scores in axial spondyloarthritis. It would be useful to identify the disease activity scores and/or laboratory biomarkers that objectively reflect inflammation on MRI. <h3>Objectives</h3> To identify the clinical disease activity scores and laboratory markers that best reflect magnetic resonance imaging (MRI)-determined sacroiliac joint (SIJ) inflammation in ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). <h3>Methods</h3> This cross-sectional study included all consecutive patients who presented with axial spondyloarthritis in 2013–2015. All underwent SIJ MRI. The bone marrow edema in the inflammatory lesions on MRI was scored using the SPondyloArthritis Research Consortium of Canada (SPARCC) method. Bone-specific alkaline phosphatase (BALP), serum C-terminal telopeptide of type-I collagen (sCTX-I), and inflammatory markers were measured. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) were assessed. The correlations between the MRI-determined SIJ inflammation scores and disease activity scores and laboratory variables were evaluated. <h3>Results</h3> Of the 81 patients with axSpA, 45 had AS and 36 had nr-axSpA. The AS and nr-axSpA groups did not differ in terms of disease activity scores, physical functional index, or MRI-determined SIJ inflammation. Erythrocyte sedimentation rate, C-reactive protein, and ASDAS correlated with MRI inflammatory scores in nr-axSpA but not in AS. sCTX-I correlated with MRI-determined SIJ inflammatory scores in AS only. BASDAI and BALP levels did not associate with MRI inflammatory scores in either group. Multivariate analysis showed that sCTX-I associated independently with MRI inflammatory score in AS (β=17.047, p=0.038). <h3>Conclusions</h3> Inflammatory markers and ASDAS correlated with active sacroiliitis on MRI in nr-axSpA only. In AS, only sCTX-I correlated with active inflammation on SIJ MRI. sCTX-I may be useful as a marker of objective inflammation in AS. <h3>Disclosure of Interest</h3> None declared
Infusion of angiotensin II reduces loss of glomerular capillary area in the early phase of anti-Thy-1.1 nephritis possibly via regulating angiogenesis-associated factors
Authors: Yuki Takazawa, Yohei Maeshima, Hiroyuki Kitayama, Yoshihiko Yamamoto, Hiroshi Kawachi, Fujio Shimizu, Hideki Matsui, Hitoshi Sugiyama, Yasushi Yamasaki, Hirofumi Makino
Journal: Kidney International (2005)
Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients.
Authors: Lewis R. Silverman, Pierre Fenaux, Aref Al-Kali, Maria R. Baer, Mikkael A. Sekeres, Gail J. Roboz, Gianluca Gaidano, Bart L Scott, Peter Greenberg, Uwe Platzbecker, David P. Steensma, Karl A Kreuzer, Lucy A. Godley, Robert Collins, Ehab L. Atallah, Nozar Azarnia, Guillermo Garcia-Manero
Journal: Journal of Clinical Oncology (2015)

7092 Background: ONTIME was a randomized (2:1) study of rigosertib (RIG) vs best supportive care (BSC) in 299 pts with HR-MDS who had relapsed after, failed to respond to, or progressed during hypomethylating agents (HMAs). This study showed a trend favoring RIG in the overall ITT analysis and a significant effect of RIG in the subgroup of patients with very high risk (VHR) per the IPSS-R. Methods: We examined the utility of the IPSS-R and the correlation between baseline disease characteristics and OS in 93 RIG and 41 BSC pts with IPSS-R VHR. Results: This first clinical study using IPSS-R in 2nd-line HR-MDS pts showed an effect (p < 0.001) of RIG on median OS vs BSC in not only the overall group of pts with IPSS-R VHR, but also in several subgroups defined by baseline disease characteristics (see table). Overall, adverse events (AEs) were reported in 100% of RIG pts and 95% of BSC pts with IPSS-R VHR. AEs ≥ Grade 3 in ≥ 10% of pts were: anaemia (RIG 24%, BSC 11%), thrombocytopenia (21%, 11%), febrile neutropenia (17%, 11%), neutropenia (15%, 13%), pneumonia (12%, 13%). Conclusions: IPSS-R is a useful prognostic tool for 2nd-line MDS pts. After HMA failure, MDS pts with IPSS-R VHR and certain subgroups identified by baseline disease characteristics showed an OS advantage when treated with RIG compared to BSC. Such characteristics should be considered in the design of future 2nd-line studies in MDS patients with IPSS-R VHR. Clinical trial information: NCT01241500.Median (months) OS by baseline disease characteristics in pts with IPSS-R VHR. Characteristic RIG BSC Log-rank p-value Hazard ratio (RIG/BSC) (95% CI) N OS N OS All patients with IPSS-R VHR 93 7.6 41 3.2 0.0050 0.56 (0.37-0.84) Primary HMA failure* 55 8.1 21 2.6 0.0055 0.48 (0.28-0.81) FAB classification of RAEB-t 23 5.8 9 3.4 0.0031 0.26 (0.10-0.68) ECOG performance status 0 or1 79 8.9 30 3.6 0.0006 0.44 (0.28-0.71) Bone marrow blast 20-30% 24 5.9 9 3.4 0.0020 0.25 (0.10-0.64) Hemoglobin < 9 g/dL 63 6.9 21 2.3 < 0.0001 0.30 (0.17-0.54) Platelet count ≥ 40 ×109/L 37 10.1 13 4.4 0.0009 0.27 (0.12-0.62) Neutrophil count ≥ 0.8 ×109/L 24 8.5 12 2.7 0.0038 0.29 (0.12-0.70) FAB classification of CMML 1 9.2 5 4.7 < 0.0001 -- *Failed to respond to or progressed during HMA treatment (Prebet 2011)
OP0345-PARE Growing up with arthritis – yes we can! a project of deutsche rheuma-liga in co-operation with the german arthritis research center. with financial support by the german federal ministry of health
Authors: K Cattelaens
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Every third young person with arthritis in Germany stops therapy when he or she enters adult care! Young people with arthritis have to travel long distances to care facilities, which are specialized in transition (about 30 throughout Germany). Because there are too few rheumatologists adults with arthritis often have to wait long for a consultation. Too few doctors have experience with treating young persons with arthritis. The situation of young persons with arthritis results in little knowledge about the condition – only every second young person knows their correct diagnosis. Parents manage everything – only every 5th young person up to 17 years has been alone with their doctor without their parents. Timely and comprehensive support is lacking. <h3>Objectives</h3> Supported by the health ministry and in cooperation with the German Arthritis Research Center the project started in 2014. As a first step the need for support for young person with arthritis was explored. It took two years to develop a pilot project with transition peers, a homepage, camps and information material for parents and doctors. The main goal of the project is to reduce the number of young persons who discontinue care because of the necessary change from children9s care to adult care. <h3>Methods</h3> Ten transition peers have been trained for providing support (telephone, online, personal). An online information platform www.mein-rheuma-wird-erwachsen.de(my arthritis is growing up!) was created, filled with the experiences of the peers, information and quizzes and contact offerings. Camps especially for young persons growing up with arthritis took place. For the parents information material were developed and a seminar: learn to let go! is offered to them. The transition peers are going to doctors congresses to spread information material and to present the homepage. <h3>Results</h3> An evaluation of the project is carried out by the German Arthritis Research Center. The online information platform is accepted, it had more than 10.000 visitors during the first year. The young users like the content of the homepage, the transition peers are accepted by the young people as well as by the doctors. <h3>Conclusions</h3> The model project is running for three years – from 2014 until the end of 2017. A subsequent project will focus on the communication between doctors and young patients and should continue the new activities for the young persons with arthritis, their parents and the doctors. <h3>References</h3> In 2016, the German rheumatology newspaper – "Zeitschrift für Rheumatologie" Nr. 6 /2016, Page 635f reported on the project with the title "Transition from pediatric to adult rheumatological care" and about the special offers from Deutsche Rheuma-Liga by Prof. Kirsten Minden and Martina Niewerth. <h3>Disclosure of Interest</h3> None declared
Narrow-Complex Tachycardia in a Woman With a 20-Year History of Supraventricular Tachycardia
Authors: Niyada Naksuk, Krishna Kancharla, Malini Madhavan
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Annals Consult Guys - Abdominal Aortic Aneurysm: When to Screen? When to Follow?
Authors: Geno J. Merli, Howard H. Weitz
Journal: Annals of Internal Medicine (2017)

Web Exclusives19 September 2017Annals Consult Guys - Abdominal Aortic Aneurysm: When to Screen? When to Follow?FREEGeno J. Merli, MD and Howard H. Weitz, MDGeno J. Merli, MDSearch for more papers by this author and Howard H. Weitz, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0009 SectionsSupplemental MaterialAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Annals Consult Guys brings a new perspective to the art and science of medicine with lively discussion and analysis of real-world cases and situations. They address medically relevant topics—whether they be poignant, thought-provoking, or just plain entertaining.For more videos from and information on Annals Consult Guys, visit go.annals.org/ConsultGuys. Comments0 CommentsSign In to Submit A Comment Linda BickAPC18 November 2019 Good This was very concise and well presented. Royce Morrison MDconsultant in clinical trial safety27 April 2020 Re-image before travel? Dear Guys, Aware that older patients - i.e., the population with more prevalence of AAA under surveillance - enjoy post-children and post-retirement travel, does that affect your recommendations for follow-up imaging of AAA? Would plans to extended travel in 2nd or 3rd world countries motivate rechecking that 3.8 cm AAA sooner than 2-3 years after the last imaging test? Would insurance carriers pay for that? Author, Article, and Disclosure InformationAffiliations: Disclosures: Geno J. Merli, MD, reports the following: Research grants/contracts: Bristol-Myers Squibb, Janssen, Portola; Consultancies: Bristol-Myers Squibb, Janssen. Howard H. Weitz, MD, reports that he has no financial relationships or interests to disclose. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 19 September 2017Volume 167, Issue 6Page: CG1KeywordsAbdominal aortic aneurysmDisclosureResearch grantsResearch reporting guidelines ePublished: 19 September 2017 Issue Published: 19 September 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
FRI0376 Differences in right ventricular function and morphology in SSC-PAH and IPAH assessed by right heart catheterization and cardiac MRI
Authors: A-M Hoffmann-Vold, E Hopp, Ø Midtvedt, T Garen, P Szodoray, Ø Molberg, AK Andreassen
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Systemic sclerosis (SSc) is a serious disorder with high mortality, mainly driven by cardiopulmonary pathologies including <i>pulmonary arterial hypertension (PAH)</i>. Patients with SSc-PAH appear to have worse prognosis than idiopathic PAH (iPAH). <h3>Objectives</h3> (A)Compare cardiac magnetic resonance (CMR) of the right ventricle, hemodynamic parameters and immunological markers between patient cohorts with SSc-PAH, iPAH and SSc without PAH, respectively. (B)Evaluate the impact of these variables on PAH-related morbidity and mortality. <h3>Methods</h3> The study cohort included SSc-PAH (n=16), iPAH (n=15) and SSc without PAH (n=20). At baseline, all patients were examined by ventricular volumes by short axis summation of cine CMR, echocardiography and right heart catheterization (RHC). Blood samples were analysed for immune-related factors. At a median follow up of 3 years, clinical data, and new onset of PAH and vital status were registered. A composite outcome for PAH related events was created including: PAH progression, end-stage PAH, hospitalization for PAH worsening and all-cause mortality. Associations between parameters were assessed using ANOVA, Pearson Chi-square, Fishers exact, or independent sample t-test. <h3>Results</h3> Patients with SSc-PAH were significantly older at PAH onset, had lower 6MWD, DLCO% and Hb than the iPAH patients. RHC results are shown in Table 1. CMR showed that SSc-PAH patients had lower right ventricular mass index (RVMI), RV to left ventricular ratio and RV mass to volume ratio (Table 1). Multiplex immune assays demonstrated higher serum levels of IP-10, VEGF and, IL12 in SSc-PAH than in iPAH. At the end of the study, 12/15 SSc-PAH had developed a PAH-related event. Compared to event-free patients, they were marked by significant CMR changes including higher RVM (p=0.006) and RVMI (p=0.005). In the iPAH subgroup, 7/16 patients developed an event. These patients were characterized by younger age at onset (p=0.001), higher NT-proBNP (p=0.017), lower 6MWD (p=0.034), higher RVM (p=0.010), RVMI (p=0.005), RV-to-LV ratio (p=0.001) on CMR. <h3>Conclusions</h3> The CMR measures indicate that the RV adapts differently in iPAH and SSc-PAH; with more pronounced RV hypertrophy in iPAH patients. The mechanisms behind the differences in RV hypertrophy in SSc-PAH and iPAH are not known, but may involve microvascular changes and deregulated inflammatory cascades. This study indicates that CMR may predict PAH progression in SSc. <h3>Disclosure of Interest</h3> None declared
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia
Authors: Vanessa Zurli, Giuliana Wimmer, Francesca Cattaneo, Veronica Candi, Emanuele Cencini, Alessandro Gozzetti, Donatella Raspadori, Giuseppe Campoccia, Francesca Sanseviero, Monica Bocchia, Cosima Tatiana Baldari, Anna Kabanova
Journal: Blood (2017)
Epiregulin Promotes Lung Metastasis of Salivary Adenoid Cystic Carcinoma
Authors: Wen-Wen Yang, Lin-Qian Yang, Fei Zhao, Chu-Wen Chen, Li-Hua Xu, Jia Fu, Sheng-Lin Li, Xi-Yuan Ge
Journal: Theranostics (2017)

Salivary adenoid cystic carcinoma (SACC) is a peculiar malignant tumor, characterized by its slow but inexorable growth, with a high incidence of lung metastasis and poor prognosis. Here, we show the upregulated expression of EGFR ligand epiregulin in a subset of SACC cells correlates with lung metastasis and unfavorable outcome in patients with SACC. We found that upregulation of epiregulin in SACC cells induced epithelial-mesenchymal transition by regulating GLI1/E-cadherin. Elevated epiregulin increased the expression of pro-angiogenic factors, such as VEGFA, bFGF, and IL-8. We also show that epiregulin can be delivered via exosomes and was enriched in exosomes derived from epiregulin-overexpressing SACC cells. Furthermore, treating immunodeficient mice with these epiregulin-enriched exosomes greatly enhanced SACC metastasis to lung. These epiregulin-enriched exosomes significantly enhanced angiogenesis in the neighboring tumor microenvironment and increased vascular permeability in the pre-metastatic lung microenvironment in vivo. Therefore, epiregulin, as well as epiregulin-containing exosomes, may be a novel target for controlling SACC lung metastasis.
FRI0224 Rituximab selectively reduces igg4 levels in rheumatoid arthritis patients
Authors: A Sarantopoulos, I Gkougkourelas, M Mytilinaiou, P Klonizakis, A Georgiadou, P Boura
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Rituximab has been applied as a therapeutic strategy in a variety of diseases, including Rheumatoid Arthritis (RA) and IgG4-Related Disease (IgG4-RD)<sup>1</sup>. On IgG4-RD, it has been shown that apart from B-cell depletion, rituximab induces remission by reducing IgG4 levels<sup>2</sup>. <h3>Objectives</h3> On this regard, we investigated weather B-cell depletion in RA is also associated with a selective reduction of any IgG subclass, especially IgG4. <h3>Methods</h3> 31 RA patients, 25/6 female/male, median age 59 years (34–73), duration of disease 9,5 years (1–30) on standard of care DMARD treatment and rituximab administration every 6 months for 2 years were investigated for alterations on disease activity along with Igs9 and IgG subclasses levels. All parameters were assessed at enrollment (T0), and after 6, 12 and 24 months. On this 2-year period all patients had been periodically receiving rituximab every 6 months. <h3>Results</h3> After 2 years of rituximab administration, patients achieved a good response to treatment (EULAR criteria). Igs9 levels were not statistically altered, though all of them declined (data for IgM and IgA not shown). Furthermore, from IgG subclasses, only IgG4 levels statistically declined. <h3>Conclusions</h3> This is the first time that IgG4 variations are investigated in a non-IgG4RD after rituximab administration. Our results imply that IgG4 may be actively implicated in RA pathophysiology, since disease remission is accompanied by only IgG4 level reduction among all classes and subclasses of Igs9. Furthermore, in RA patients, rituximab may exert its therapeutic results not only via B-cell depletion, but also via IgG4 levels reduction. <h3>References</h3> Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015 Jun;74(6):1171–7. Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab Therapy Leads to Rapid Decline of Serum IgG4 Levels and Prompt Clinical Improvement in IgG4-Related Systemic Disease. Arthritis Rheum. 2010 Jun; 62(6): 1755–62. <h3>Disclosure of Interest</h3> None declared
AB1035 Examination of ultrasound findings in undifferentiated spondyloarthritis patients with dactylitis
Authors: K Fujikawa, Y Endo, A Mizokami, M Mine, A Kawakami
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> To evaluate the ultrasound findings in undifferentiated spondyloarthritis (uSpA) patients with or without dactylitis. <h3>Methods</h3> Between April 2014 and December 2016, sixty-six patients with uSpA diagnosed at our center were consecutively enrolled. The diagnosis of uSpA was made by the Japan College of Rheumatology (JCR)-certified rheumatologists and dactylitis was defined as sausage-digit appearance. Ultrasound, clinical and laboratory findings at diagnosis in patients with dactylitis (dactylitis group; n=30) were compared to those without dactylitis (non-dactylitis group; n=36). Grey scale (GS) and power Doppler (PD) signals of the wrist and finger joints, PD signal of extensor and flexor tendon sheaths, and PD signals of the collateral ligament of the fingers in both hands were assessed by ultrasound. Ultrasound assessment was made by JCR-registered sonographers. <h3>Results</h3> There were no significant differences in clinical and laboratory findings, including inflammatory back pain, arthritis of the lower limbs, tenderness of the entheses, radiographic/MRI changes of sacroiliac joint and HLA-B27 allele frequency, between two groups. In ultrasound findings, the dactylitis group had significantly more PD signals of the flexor tendon sheaths (83% vs. 22%, p&lt;0.0001), the collateral ligament (83% vs. 25%, p&lt;0.0001), and the MCP joint (30% vs. 3%, p&lt;0.01) as compared with the non-dactylitis group. In logistic regression analysis, the PD signals of the flexor tendons and collateral ligament were independent contributors to a diagnosis of dactylitis (Figure 1). <h3>Conclusions</h3> Development of active inflammation of enthesis organ determined by ultrasound is supposed to associate importantly with the judgment as dactylitis in patients with uSpA. <h3>Disclosure of Interest</h3> None declared